Volume : 9, Issue : 9, SEP 2023

DRUG RESISTANCE IN CANCER CHEMOTHERAPY : AN UPDATED REVIEW

PRIYANKA MAPARI*, DR. N. V. SHINDE, DAYALI PAGARE

Abstract

Cancer is a second leading cause of death in the world and chemotherapy is a backbone of treatment for many cancers at various stages. Cancer chemotherapy, a cornerstone of oncology, is frequently hindered by the development of drug resistance. Resistance to chemotherapy is due to variety of factors including individual differences in patient and genetic variances in tumors. The most common cause of drug resistance is a change in expression of one or more energy dependent transporters, insensitivity to drug-induced apoptosis and the production of drug-detoxifying effects. Understanding the complex interplay of intrinsic and extrinsic resistance mechanisms is critical for developing effective treatment strategies to avoid treatment failure. The discovery of specific biomarkers linked to drug resistance can help to inform targeted treatment approaches, allowing chemotherapy regimens to be tailored to individual patients. Furthermore, research into novel drug delivery systems and combination therapies holds promise for overcoming drug resistance challenges.

This review project outlines Status of cancer in the world, types of cancer, various treatments available and drugs available in the market. It also focuses on various aspects of drug resistance in cancer chemotherapy including causes, mechanism of drug resistance and strategies to overcome such drug resistance. This review also includes current knowledge on drug resistance in cancer chemotherapy, providing an in-depth review of the interaction of intrinsic and extrinsic factors. This work aims to inspire innovative therapeutic approaches and facilitate the development of more effective, particular cancer treatment strategies by elucidating the intricate molecular and environmental determinants of resistance.

Article : Download PDF

Cite This Article

-

Article No : 12

Number of Downloads : 427

References

1. S. S. Vairagkar, S. B. Bavage, N. B. Bavage, and P. G. Vidyasagar, “Cancer review article,” vol. 7, no. 11, pp. 619–626, 2021.

2. Robert A. Weinberg, “How cancer arises,” Sci. Am. Div. Nat. Am., vol. 275, no. 3, pp. 61–61, 1996, [Online]. Available: https://www.jstor.org/stable/10.2307/24993349%

3. B. Mansoori, A. Mohammadi, S. Davudian, S. Shirjang, and B. Baradaran, “The different mechanisms of cancer drug resistance: A brief review,” Adv. Pharm. Bull., vol. 7, no. 3, pp. 339–348, 2017, doi: 10.15171/apb.2017.041.

4. Xiaomei Ma and Herbert Yu*, “Global Burden of Cancer,” YALE J. Biol. Med. 79 (2006), pp.85-94. Copyr. © 2006., vol. 79, pp. 85–94, 2006.

5. J. B. Weitzman, Cancer drug resistance Overviews and Methods, vol. 2, no. 1. 2001. doi: 10.1186/gb-spotlight-20010626-01.

6. G. J. Peters, “Cancer drug resistance: a new perspective,” Cancer Drug Resist., vol. 1, no. 1, pp. 1–5, 2018, doi: 10.20517/cdr.2018.03.

7. F. S. Liu, “Mechanisms of Chemotherapeutic Drug Resistance in Cancer Therapy-A Quick Review,” Taiwan. J. Obstet. Gynecol., vol. 48, no. 3, pp. 239–244, 2009, doi: 10.1016/S1028-4559(09)60296-5.

8. Y. A. Luqmani, “Mechanisms of drug resistance in cancer chemotherapy,” Med. Princ. Pract., vol. 14, no. SUPPL. 1, pp. 35–48, 2005, doi: 10.1159/000086183.

9. B. N. Ames, L. S. Gold, and W. C. Willett, “The causes and prevention of cancer,” Proc. Natl. Acad. Sci. U. S. A., vol. 92, no. 12, pp. 5258–5265, 1995, doi: 10.1073/pnas.92.12.5258.

10. R. L. Siegel, K. D. Miller, and A. Jemal, “Cancer statistics, 2019,” CA. Cancer J. Clin., vol. 69, no. 1, pp. 7–34, 2019, doi: 10.3322/caac.21551.

11. A. Saini, M. Kumar, S. Bhatt, and V. Saini, “INTRODUCTION?: Cancer?: Cancer is a disorder,” Int. J. Pharm. Sci. Res., vol. 11, no. July, pp. 3121–3134, 2020, doi: 10.13040/IJPSR.0975-8232.11(7).3121-34.

12. E. Hosseinzadeh, N. Banaee, and H. A. Nedaie, “Cancer and Treatment Modalities,” Curr. Cancer Ther. Rev., vol. 13, no. 1, 2017, doi:10.2174/1573394713666170531081818.

13. G. B. S. M. R. Chorawala1*, P. M. Oza2 and 1Department, “Mechanisms of Anticancer Drugs Resistance: An Overview,” J. Pharm. Technol. Drug Res., vol. 1, no. 1, p. 1, 2012, doi: 10.7243/2050-120x-1-1.

14. D. T. Debela et al., “New approaches and procedures for cancer treatment: Current perspectives,” SAGE Open Med., vol. 9, p. 205031212110343, 2021, doi: 10.1177/20503121211034366.

15. J. M. Greene, C. Sanchez-Tapia, and E. D. Sontag, “Control Structures of Drug Resistance in Cancer Chemotherapy,” Proc. IEEE Conf. Decis. Control, vol. 2018-Decem, no. Cdc, pp. 5195–5200, 2018, doi: 10.1109/CDC.2018.8618653.

16. T. R. Fenton, M. D. Garrett, M. N. Wass, and M. Michaelis, “What really matters - response and resistance in cancer therapy,” Cancer Drug Resist., vol. 1, no. 4, pp. 200–203, 2018, doi: 10.20517/cdr.2018.19.

17. M. M. Gottesman, O. Lavi, M. D. Hall, and J. P. Gillet, “Toward a Better Understanding of the Complexity of Cancer Drug Resistance,” Annu. Rev. Pharmacol. Toxicol., vol. 56, no. October 2015, pp. 85–102, 2016, doi: 10.1146/annurev-pharmtox-010715-103111.

18. I. Vincent T.Devita, JR, MD, Robert C. Young , MD and George P.Canellos M, “Combination versus single agent chemotherapy: A review of the basis for selection of drug treatment of cancer,” pp. 98–110, 1974.

19. M. Arruebo et al., “Assessment of the evolution of cancer treatment therapies,” Cancers (Basel)., vol. 3, no. 3, pp. 3279–3330, 2011, doi: 10.3390/cancers3033279.

20. S. Kumar, P. P. Kushwaha, and S. Gupta, “Emerging targets in cancer drug resistance,” Cancer Drug Resist., vol. 2, no. 2, pp. 161–177, 2019, doi: 10.20517/cdr.2018.27.

21. P. Nygren, “What is cancer chemotherapy?,” Acta Oncol. (Madr)., vol. 40, no. 2–3, pp. 166–174, 2001, doi: 10.1080/02841860151116204.

22. M. M. Gottesman, “Mechanisms of Cancer drug resistance,” arjournals.Annu. Rev. Med. 2002. 53615–27, 2002.

23. I. Marzo and J. Naval, “Antimitotic drugs in cancer chemotherapy: Promises and pitfalls,” Biochem. Pharmacol., vol. 86, no. 6, pp. 703–710, 2013, doi: 10.1016/j.bcp.2013.07.010.

24. S. T. Pan, Z. L. Li, Z. X. He, J. X. Qiu, and S. F. Zhou, “Molecular mechanisms for tumour resistance to chemotherapy,” Clin. Exp. Pharmacol. Physiol., vol. 43, no. 8, pp. 723–737, 2016, doi: 10.1111/1440-1681.12581.

25. S. Raguz and E. Yagüe, “Resistance to chemotherapy: New treatments and novel insights into an old problem,” Br. J. Cancer, vol. 99, no. 3, pp. 387–391, 2008, doi: 10.1038/sj.bjc.6604510.

26. J. and E. C. C. Vincent T. DeVita, “A history of cancer chemotherapy,” Cancer Res., vol. 68, no. 21, pp. 8643–8653, 2008, doi: 10.1158/0008-5472.CAN-07-6611.

27. M. B. Sporn, “The war on cancer,” Lancet, vol. 347, no. 9012, pp. 1377–1381, 1996, doi: 10.1016/S0140-6736(96)91015-6.

28. K. Bukowski, M. Kciuk, and R. Kontek, “Mechanisms of multidrug resistance in cancer chemotherapy,” Int. J. Mol. Sci., vol. 21, no. 9, 2020, doi: 10.3390/ijms21093233.

29. M. S. Aslam, S. Naveed, A. Ahmed, Z. Abbas, I. Gull, and M. A. Athar, “Side Effects of Chemotherapy in Cancer Patients and Evaluation of Patients Opinion about Starvation Based Differential Chemotherapy,” J. Cancer Ther., vol. 05, no. 08, pp. 817–822, 2014, doi: 10.4236/jct.2014.58089.

30. H. Akhdar, C. Legendre, C. Aninat, and F. More, “Anticancer Drug Metabolism: Chemotherapy Resistance and New Therapeutic Approaches,” Top. Drug Metab., 2012, doi: 10.5772/30015.

31. A. C. S. A. W. A. CREASEY, “Cancer chemotherapy.,” Annu. Rev. Pharmacol., vol. 9, pp. 51–72, 1969, doi: 10.1146/annurev.pa.09.040169.000411.

32. A. R. Hamed, N. S. Abdel-Azim, K. A. Shams, and F. M. Hammouda, “Targeting multidrug resistance in cancer by natural chemosensitizers,” Bull. Natl. Res. Cent., vol. 43, no. 1, 2019, doi: 10.1186/s42269-019-0043-8.

33. K. O. Alfarouk et al., “Resistance to cancer chemotherapy: Failure in drug response from ADME to P-gp,” Cancer Cell Int., vol. 15, no. 1, pp. 1–13, 2015, doi: 10.1186/s12935-015-0221-1.

34. K. M. Redmond, T. R. Wilson, P. G. Johnston, and D. B. Longley, “Drug Resistance Laboratory, Centre for Cancer Research and Cell Biology, Queen’s University Belfast, Belfast, UK,” pp. 5138–5154, 2008.

35. V. Karavasilis, A. Reid, R. Sinha, and J. S. de Bono, “Cancer drug resistance,” Cancer Drug Des. Discov., pp. 405–423, 2008, doi: 10.1016/B978-012369448-5.50020-3.

36. M. Nikolaou, A. Pavlopoulou, A. G. Georgakilas, and E. Kyrodimos, “The challenge of drug resistance in cancer treatment: a current overview,” Clin. Exp. Metastasis, vol. 35, no. 4, pp. 309–318, 2018, doi: 10.1007/s10585-018-9903-0.

37. R. Brown and M. Links, “Clinical relevance of the molecular mechanisms of resistance to anti-cancer drugs,” Expert Rev. Mol. Med., vol. 1, no. 15, pp. 1–21, 1999, doi: 10.1017/S1462399499001099X.

38. S. Sawant and R. Shegokar, “Cancer research and therapy?: Where are we today?? Cancer research and therapy?: Where are we today?? Review Article Abstract,” no. October, 2014, doi: 10.14319/ijcto.0204.8.

39. G. Housman et al., “Drug resistance in cancer: An overview,” Cancers (Basel)., vol. 6, no. 3, pp. 1769–1792, 2014, doi: 10.3390/cancers6031769.

40. H. R. Mellor and R. Callaghan, “Resistance to chemotherapy in cancer: A complex and integrated cellular response,” Pharmacology, vol. 81, no. 4, pp. 275–300, 2008, doi: 10.1159/000115967.

41. S. Garattini*, “Pharmacokinetics in cancer chemotherapy,” Eur. J. Cancer, vol. 43, no. 2, pp. 271–282, 2007, doi: 10.1016/j.ejca.2006.10.015.

42. N. L. Komarova and D. Wodarz, “Drug resistance in cancer: Principles of emergence and prevention,” Proc. Natl. Acad. Sci. U. S. A., vol. 102, no. 27, pp. 9714–9719, 2005, doi: 10.1073/pnas.0501870102.

43. H. M. P. Giuseppe glaccone, “Drug resistance.,” Curr. Opin. Oncol., vol. 1, no. 2, pp. 236–240, 1989, doi: 10.1634/theoncologist.1-1-82.

44. T. H. Lippert, H. J. Ruoff, and M. Volm, “Intrinsic and acquired drug resistance in malignant tumors: The main reason for therapeutic failure,” Arzneimittel-Forschung/Drug Res., vol. 58, no. 6, pp. 261–264, 2008, doi: 10.1055/s-0031-1296504.

45. U. Ledzewicz and H. Schättler, “Drug resistance in cancer chemotherapy as an optimal control problem,” Discret. Contin. Dyn. Syst. - Ser. B, vol. 6, no. 1, pp. 129–150, 2006, doi: 10.3934/dcdsb.2006.6.129.

46. X. Wang, H. Zhang, and X. Chen, “Drug resistance and combating drug resistance in cancer,” Cancer Drug Resist., vol. 2, no. 2, pp. 141–160, 2019, doi: 10.20517/cdr.2019.10.

47. R. Ankathil, “Cite this article: Ravindran Ankathil. 2019. The Mechanisms and Challenges of Cancer Chemotherapy Resistance: A Current Overview,” Eur. J. Mol. Clin. Med., vol. 6, no. 1, pp. 26–34, 2019.

48. A. Shehzad, Cancer Biomarkers in Diagnosis and Therapeutics. 2022. doi: 10.1007/978-981-16-5759-7.

49. C. Holohan, S. Van Schaeybroeck, D. B. Longley, and P. G. Johnston, “Cancer drug resistance: An evolving paradigm,” Nat. Rev. Cancer, vol. 13, no. 10, pp. 714–726, 2013, doi: 10.1038/nrc3599.

50. T. Ozben, “Mechanisms and strategies to overcome multiple drug resistance in cancer,” FEBS Lett., vol. 580, no. 12, pp. 2903–2909, 2006, doi: 10.1016/j.febslet.2006.02.020.

51. M. Kartal-Yandim, A. Adan-Gokbulut, and Y. Baran, “Molecular mechanisms of drug resistance and its reversal in cancer,” Crit. Rev. Biotechnol., vol. 36, no. 4, pp. 716–726, 2016, doi: 10.3109/07388551.2015.1015957.

52. M. F. Ullah, “Cancer multidrug resistance (MDR): A major impediment to effective chemotherapy,” Asian Pacific J. Cancer Prev., vol. 9, no. 1, pp. 1–6, 2008.

53. N. H. Patel and M. L. Rothenberg, “Multidrug resistance in cancer chemotherapy,” Invest. New Drugs, vol. 12, no. 1, pp. 1–13, 1994, doi: 10.1007/BF00873229.

54. K. Nooter and G. Stoter, “Molecular mechanisms of multidrug resistance in cancer chemotherapy,” Pathol. Res. Pract., vol. 192, no. 7, pp. 768–780, 1996, doi: 10.1016/S0344-0338(96)80099-9.

55. N. Vasan, J. Baselga, and D. M. Hyman, “A view on drug resistance in cancer,” Nature, vol. 575, no. 7782, pp. 299–309, Nov. 2019, doi: 10.1038/s41586-019-1730-1.

56. M. Filipits, “Mechanisms of cancer: Multidrug resistance,” Drug Discov. Today Dis. Mech., vol. 1, no. 2, pp. 229–234, 2004, doi: 10.1016/j.ddmec.2004.10.001.

57. R. Vadlapatla, A. Vadlapudi, D. Pal, and A. Mitra, “Mechanisms of Drug Resistance in Cancer Chemotherapy: Coordinated Role and Regulation of Efflux Transporters and Metabolizing Enzymes,” Curr. Pharm. Des., vol. 19, no. 40, pp. 7126–7140, 2013, doi: 10.2174/13816128113199990493.

58. Q. Wu, Z. Yang, Y. Nie, Y. Shi, and D. Fan, “Multi-drug resistance in cancer chemotherapeutics: Mechanisms and lab approaches,” Cancer Lett., vol. 347, no. 2, pp. 159–166, 2014, doi: 10.1016/j.canlet.2014.03.013.

59. P. Borst, “Genetic mechanisms of drug resistance: A review,” Acta Oncol. (Madr)., vol. 30, no. 1, pp. 87–105, 1991, doi: 10.3109/02841869109091819.

60. H. Zahreddine and K. L. B. Borden, “Mechanisms and insights into drug resistance in cancer,” Front. Pharmacol., vol. 4 MAR, no. March, pp. 1–8, 2013, doi: 10.3389/fphar.2013.00028.

61. M. G. Ira Pastan,M.D., “Multiple - drug resistance in cancer human cancer,” N. Engl. J. Med., no. 320, pp. 915–924, 1989.

62. S. S. Kesharwani, S. Kaur, H. Tummala, and A. T. Sangamwar, “Overcoming multiple drug resistance in cancer using polymeric micelles,” Expert Opin. Drug Deliv., vol. 15, no. 11, pp. 1127–1142, 2018, doi: 10.1080/17425247.2018.1537261.

63. M. Majidinia et al., “Overcoming multidrug resistance in cancer: Recent progress in nanotechnology and new horizons,” IUBMB Life, vol. 72, no. 5, pp. 855–871, 2020, doi: 10.1002/iub.2215.

64. I. A. Cree and P. Charlton, “Molecular chess? Hallmarks of anti-cancer drug resistance,” BMC Cancer, vol. 17, no. 1, pp. 1–8, 2017, doi: 10.1186/s12885-016-2999-1.

65. B. Zhitomirsky and Y. G. Assaraf, “Lysosomes as mediators of drug resistance in cancer,” Drug Resist. Updat., vol. 24, pp. 23–33, 2016, doi: 10.1016/j.drup.2015.11.004.

66. A. Kumar, U. K. Singh, and A. Chaudhary, “Targeting autophagy to overcome drug resistance in cancer therapy,” Future Med. Chem., vol. 7, no. 12, pp. 1535–1542, 2015, doi: 10.4155/fmc.15.88.

67. R. Yuan et al., “Natural products to prevent drug resistance in cancer chemotherapy: a review,” Ann. N. Y. Acad. Sci., vol. 1401, no. 1, pp. 19–27, 2017, doi: 10.1111/nyas.13387.

68. M. Saraswathy and S. Gong, “Author ’ s personal copy Different strategies to overcome multidrug resistance in cancer”.

69. R. Zeng and J. Dong, “The hippo signaling pathway in drug resistance in cancer,” Cancers (Basel)., vol. 13, no. 2, pp. 1–23, 2021, doi: 10.3390/cancers13020318.

70. A. K. Iyer, A. Singh, S. Ganta, and M. M. Amiji, Role of integrated cancer nanomedicine in overcoming drug resistance, vol. 65, no. 13–14. Elsevier B.V., 2013. doi: 10.1016/j.addr.2013.07.012.

71. Q. He and J. Shi, “MSN anti-cancer nanomedicines: Chemotherapy enhancement, overcoming of drug resistance, and metastasis inhibition,” Adv. Mater., vol. 26, no. 3, pp. 391–411, 2014, doi: 10.1002/adma.201303123.